Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future

TY - JOUR

T1 - Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease

T2 - Past, Present, and Future

AU - Tan, Yu Yan

AU - Jenner, Peter

AU - Chen, Sheng Di

N1 - Funding Information: This work was supported by the National Natural Science Foundation of China, Grant/Award Number: 81430022, 81771374, 81971187, 81971183; Shanghai Municipal Science and Technology Major Project, Grant/Award Number: 2018SHZDZX05; Innovation Program of Shanghai Municipal Education Commission, Grant/Award Number: 2017-01-07-00-01-E00046; Foundation of Shanghai Municipal Education Commission, Grant/Award Number: 2017NKX001. Publisher Copyright: © 2022 - The authors. Published by IOS Press.

PY - 2022

Y1 - 2022

N2 - Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce 'OFF' time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.

AB - Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce 'OFF' time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.

KW - Monoamine oxidase-B inhibitors

KW - Parkinson's disease

KW - rasagiline

KW - safinamide

KW - selegiline

UR - http://www.scopus.com/inward/record.url?scp=85125001235&partnerID=8YFLogxK

U2 - 10.3233/JPD-212976

DO - 10.3233/JPD-212976

M3 - Review article

C2 - 34957948

AN - SCOPUS:85125001235

SN - 1877-7171

VL - 12

SP - 477

EP - 493

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 2

ER -